Literature DB >> 3887163

Pathogenesis and management of lipoprotein disorders.

E J Schaefer, R I Levy.   

Abstract

Mesh：

Substances：

Year:  1985        PMID： 3887163     DOI： 10.1056/NEJM198505163122007

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  35 in total

Review 1.  Molecular aspects of pathological processes in the artery wall.

Authors:  J W van Neck; H P Bloemers
Journal:  Mol Biol Rep       Date:  1992-11       Impact factor: 2.316

Review 2.  A comparative review of the adverse effects of treatments for hyperlipidaemia.

Authors:  A Steiner; B Weisser; W Vetter
Journal:  Drug Saf       Date:  1991 Mar-Apr       Impact factor: 5.606

3.  Fibrates and HMG-CoA reductase inhibitors.

Authors:  M W Huff
Journal:  CMAJ       Date:  1991-10-15       Impact factor: 8.262

4.  The effect on serum lipid concentrations of a prolonged infusion of propofol--hypertriglyceridaemia associated with propofol administration.

Authors:  J M Eddleston; M P Shelly
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

Review 5.  Lipid lowering drugs.

Authors:  P O'Connor; J Feely; J Shepherd
Journal:  BMJ       Date:  1990-03-10

Review 6.  Atherosclerosis: the eicosanoid connection.

Authors:  A N Makheja
Journal:  Mol Cell Biochem       Date:  1992-04       Impact factor: 3.396

7.  A physician's guide to lipoprotein metabolism.

Authors:  J A Little
Journal:  CMAJ       Date:  1989-09-15       Impact factor: 8.262

Review 8.  Cholesterol and heart disease: current concepts in pathogenesis and treatment.

Authors:  L T Clark
Journal:  J Natl Med Assoc       Date:  1986-08       Impact factor: 1.798

Review 9.  Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia.

Authors:  M M Buckley; K L Goa; A H Price; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

Review 10.  Lipid-lowering drugs. An overview of indications and optimum therapeutic use.

Authors:  D R Illingworth
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.